Tern Plc secures extension on £120,000 loan balance

TERN

Tern Plc (LON:TERN), the investment company specialising in supporting high growth, early-stage, disruptive Internet of Things technology businesses, has announced that the repayment date of the loan facility agreement originally announced on 12 June 2023 has been extended, with the agreement of the Loan provider, to 11 September 2026.  The Board considers that the extension gives the Company greater negotiating flexibility in relation to funding the future capital requirements of its investee companies.  Since being entered into the Loan has been varied twice previously, as announced on 4 September 2024 and 15 September 2025.

The Company has agreed to make a payment of £38,432.88 to the Loan provider as a partial repayment of the outstanding Loan balance and accrued interest, plus a Loan extension fee of £6,000. Following these payments £120,000 will remain outstanding under the Loan and this amount, plus accrued interest at a rate of 1.00% per calendar month, will be repayable by the Company on or before 11 September 2026.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Device Authority strengthens position in machine identity and Zero Trust Security

Device Authority’s inclusion in two 2026 Gartner Hype Cycle reports reinforces its positioning in machine identity, IoT authentication and Zero Trust security.

Talking Medicines highlights strategic value of patient journey intelligence

Patient journey intelligence can help healthcare organisations identify care barriers and design more responsive pathways around real patient experiences.

Evidence-based care pathways support more consistent healthcare delivery

Evidence-based care pathways can improve diagnosis, treatment consistency and the integration of new therapies into routine care.

Tern increases Talking Medicines funding and raises shareholder distribution commitment

Tern has invested in additional Talking Medicines convertible loan notes and increased its minimum shareholder distribution commitment to 70% on qualifying exits.

Evidence-based care pathways create clearer routes to adoption

Evidence-based care pathways can reduce delays, improve treatment consistency and support the adoption of new therapies.

Talking Medicines highlights the data opportunity emerging around GLP-1 care

Talking Medicines examines how the expanding GLP-1 market is increasing the importance of clear distinctions between approved therapies, compounded medicines and nutritional support.

Search